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Abstract
Background: The State Innovation Models (SIM) Initiative invested $254 million in 6 states in 
Round 1 to accelerate delivery system and payment reforms.
Objectives: To examine the association of early SIM implementation and diagnosed diabetes 
prevalence among adults and hospitalization rates among diagnosed adults.
Research Design: Quasi-experimental design compares diagnosed diabetes prevalence and 
hospitalization rates before SIM (2010–2013) and during early implementation (2014) in 6 SIM 
states versus 6 comparison states. County-level, difference-in-differences regression models were 
estimated.
Subjects: Annual average of 4.5 million adults aged 20+ diagnosed with diabetes with 1.4 
million hospitalizations in 583 counties across 12 states
Measures: Diagnosed diabetes prevalence among adults and hospitalization rates per 1000 
diagnosed adults
Results: Compared with the pre-SIM period, diagnosed diabetes prevalence increased in SIM 
counties by 0.65 percentage points (from 10.22% to 10.87%) versus only 0.10 percentage points 
(from 9.64% to 9.74%) in comparison counties, a difference-in-differences of 0.55 percentage 
points. The difference-in-differences regression estimates ranged from 0.49 to 0.53 percentage 
points (P<0.01). Regression results for ambulatory care-sensitive condition and all-cause 
hospitalization rates were inconsistent across models with difference-in-differences estimates 
ranging from −5.34 to −0.37 and from −13.16 to 0.92, respectively.
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Conclusions: SIM Round 1 was associated with higher diagnosed diabetes prevalence among 
adults after a year of implementation, likely because of SIM’s emphasis on detection and care 
management. SIM was not associated with lower hospitalization rates among adults diagnosed 
with diabetes, but SIM’s long-term impact on hospitalizations should be assessed.
Abstract
Summary: CMS’s State Innovation Model Initiative was associated with higher diagnosed diabetes 
prevalence, likely from its emphasis on detection.
Keywords
diabetes; diagnosis; utilization; preventable hospitalizations; quasi-experimental design; policy 
evaluation
I. Background and Objectives
The State Innovation Models (SIM) Initiative was launched by Centers for Medicare and 
Medicaid Services (CMS) to accelerate health system transformation (1–4). The SIM 
Initiative is an ongoing, naturally occurring federal-state “policy intervention” that provides 
financial and technical support to states for developing and testing state-led multipayer 
health care payment and service delivery models. The goals SIM are to improve health 
system performance, improve the quality of patient care, and decrease health care costs for 
all residents of the state. SIM states have emphasized different strategies to achieve their 
goals, including value-based payment models, accountable care organizations, health homes 
for individuals needing behavioral health services, and regional collaborations of medical 
and long-term service and support providers (1).
In order to achieve SIM Initiative’s goals, most SIM states accelerated their activities related 
to delivery system and payment reform strategies in order to improve the detection and 
management of chronic conditions, and in particular, diabetes because of its large 
contribution to patient morbidity and health care costs (5, 6). All state SIM plans included 
outcome and utilization performance measures focused on adults with diabetes (1, 2, 4).
Improving diabetes detection and management for adults with diabetes is a focus of most 
states’ SIM plans, because of diabetes’ increasing prevalence during the past 3 decades (7). 
In 2017, an estimated 24.6 million adults (or 9.7%) have been diagnosed, incurring $236 
billion in direct medical costs attributable to diabetes, of which, ~29% were for hospital 
inpatient costs (5). In 2014, there were 7.2 million hospitalizations of adults with a diabetes 
diagnosis, a rate of 327 hospitalizations per 1000 diagnosed adults (8).
The 3 types of SIM awards include Design Awards that fund states to design a State Health 
Care Innovation Plan, Pre-Test Awards that fund states to continue developing their State 
Health Care Innovation Plans, and Test Awards that funds states to test and implement 
delivery system reforms. Since 2013, these awards have invested > 1 billion dollars in states’ 
efforts to design, test and implement delivery system reforms. The SIM Initiative is now 
supporting the testing and implementation of SIM plans in 17 states: in April 2013, 6 states 
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received 42 months of test-award funding totaling $254 million (“Round 1” states); in 
January 2015, 11 states received 48 months of test-award funding totaling $622 million 
(“Round 2” states) (9).
In this study, we analyze whether counties in states that received a SIM test award in Round 
1 experienced an increase in diagnosed diabetes prevalence among adults and a decrease in 
hospitalization rates among diagnosed adults, relative to a select group of counties in 
comparison states that applied for SIM funding, but did not receive a SIM test award in 
Round 1, although eventually did in Round 2. These research questions are of interest, 
because SIM may have accelerated improvements in the detection and management of 
diabetes—either by directly targeting diabetes or targeting chronic conditions more broadly
—resulting in a higher diagnostic prevalence and lower hospitalization rates among 
diagnosed adults.
Our hypotheses are:
Hypothesis 1: The SIM Initiative improved the detection of diabetes in the short-term, 
resulting in more adults being diagnosed with diabetes; and
Hypothesis 2: The SIM Initiative improved the management of diabetes in the short-term, 
resulting in fewer hospitalizations among adults diagnosed with diabetes.
II. Methods
II.A. Measures
II.A.1. Outcome Variables—The outcome variables include diagnosed diabetes 
prevalence among adults, ambulatory care-sensitive condition (ACSC) hospitalizations per 
1000 diagnosed adults, and all-cause hospitalizations per 1000 diagnosed adults. These 
outcomes were measured at the county-year level for adults (aged 20+ y old) from 2010 to 
2014, because that was the geographic level and frequency of the diagnostic prevalence data 
(discussed below). An adult was considered diagnosed with diabetes based on their response 
to the Behavioral Risk Factor Surveillance System question that asked “Has a doctor ever 
told you that you have diabetes?”; women who only had been diagnosed with gestational 
diabetes were not considered diagnosed (10).
Hospitalizations among adults diagnosed with diabetes were identified based on Agency for 
Healthcare Research and Quality (AHRQ) specifications using the Healthcare Cost and 
Utilization Project (HCUP) Clinical Classifications Software (CCS), which categorizes 
ICD-9-CM diagnosis codes into a clinical grouper to understand patterns of diagnoses and 
procedures (11). The included hospitalizations were diabetes without complication 
(CCS=49) and diabetes with complications (CCS=50), which were extracted from up to 50 
principal and secondary diagnosis fields per patient. Hospitalizations for pregnancies and 
hospital transfers were excluded. Hospitalizations that were due to ACSCs were analyzed 
separately because these hospitalizations are considered preventable through improved 
primary care management of diabetes, which was a major focus of SIM. We identified these 
hospitalizations from ICD-9-CM codes that were extracted from the principal diagnosis field 
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of each patient using the following 2015 AHRQ Prevention Quality Indicators: #1 Diabetes 
Short-Term Complications, #3 Diabetes Long-Term Complications, #5 Chronic Obstructive 
Pulmonary Disease or Asthma in Older Adults, #7 Hypertension, #8 Heart Failure, #10 
Dehydration, #11 Bacterial Pneumonia, #12 Urinary Tract Infection, #13 Angina Without 
Procedure, #14 Uncontrolled Diabetes, #15 Asthma in Younger Adults, and #16 Lower-
Extremity Amputation among Patients with Diabetes (12). Annual county-level 
hospitalization rates were calculated by dividing the number of hospitalizations by the 
number of adults (in 1,000s) diagnosed with diabetes.
II.A.2. Key Independent Variable—The key independent variable was defined at the 
county-year level indicating whether a county was in a state that received a SIM Initiative, 
42-month test award in Round 1 and whether the year was in the post-intervention period 
(9). The 6 SIM states included Arkansas, Maine, Massachusetts, Minnesota, Oregon and 
Vermont (see Fig. A1 in the Appendix, Supplemental Digital Content 1, http://
links.lww.com/MLR/B678). SIM funding began on April 1, 2013, which included an initial 
6-month test period, resulting in the test implementation phase beginning October 1, 2013 
(1, 4). Because the diagnosed diabetes prevalence data are annual, we modeled the 
intervention period as beginning January 1, 2014. The analytic sample for the 6 SIM states 
included 240 counties from 2010 to 2014 (or 1200 county-year observations) with a mean 
adult population of 15.6 million during those years.
The comparison states included 6 states that received test awards in Round 2, whose funding 
began in January 2015 for 48 months: Colorado, Iowa, Michigan, New York, Rhode Island 
and Washington. These comparison states were selected because they were similar to the 
Round 1 test states, based on having received a design award in Round 1—thus 
demonstrating stakeholder engagement and a collaborative infrastructure for implementing 
state SIM plans—and providing data to the HCUP State Inpatient Databases. The analytic 
sample for the 6 comparison states included 343 counties from 2010 to 2014 (or 1715 
county-year observations) with a mean adult population of 34.0 million during those years.
II.B. Data
Encounter-level hospitalization data were from the State Inpatient Databases maintained by 
HCUP. These administrative data include a census of all hospitalizations in the 12 states 
comprising of 594 counties from 2010 to 2014; 11 counties were excluded for incomplete 
data resulting in 583 counties with 6.8 million hospitalizations of adults diagnosed with 
diabetes, of which, 22.5% were for ACSCs.
Data on the number and prevalence of adults diagnosed with diabetes per county-year were 
from the Centers for Disease Control and Prevention’s “County Data Indicators” (10, 13). 
The analytic sample of 583 counties included an average of 49.6 million adults from 2010 to 
2014, including an average of 4.5 million diagnosed with diabetes.
The Area Health Resources File was used to obtain data on county-level factors related to 
diagnosed diabetes prevalence and hospitalization rates, including gender, age, race/
ethnicity, uninsured rate, and poverty rate (household income < 100% of the federal poverty 
level), which were available for each county’s population.
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II.C. Analytic Approach
Hypotheses 1 and 2 were tested by estimating county-level, difference-in-differences 
regression models that had the structure of equation (1) in which c indexes counties and t 
indexes years; outcomec,t is the percentage of adults diagnosed with diabetes (Hypotheses 1) 
or the number of hospitalizations per 1000 diagnosed adults (Hypotheses 2); SIMc,t indicates 
implementation of a Round 1 SIM test award; yeart is a vector of year indicator variables for 
each year (except 2010, the reference year) to control for trends in the outcome measures 
across all counties; countyc is a vector of county fixed effects to control for time-invariant 
outcome differences among the counties; Xc,t is a vector of time-varying control variables; 
εc,t is the error term; and β1 is the parameter of interest. The Xc,t vector includes gender, 
age, race/ethnicity, uninsured rate, and poverty rate, which are known to affect diagnosed 
diabetes prevalence among adults and hospitalizations of diagnosed adults (5, 14). These 
variables are measured at the county level as means for each county’s population. The 
regression models were not weighted for a county’s population so that each county would be 
considered an equal unit of analysis. Standard errors were estimated by clustering at the 
county level to allow for correlation within counties across time (15).
outcomec, t = β0 + β1SIMc, t + β2yeart + β3countyc + β4Xc, t + εc, t (1)
The first set of difference-in-differences models are from equation (1). This model controls 
for time-invariant outcome differences between SIM and comparison counties, secular 
outcome trends, and time-varying cofounding variables. However, it does not control for pre-
intervention differences that affect the post-intervention period, manifesting in two distinct 
concerns.
First, there is concern if pre-intervention outcome trends are not parallel between SIM and 
comparison counties—and those non-parallel trends would have persisted in the post-
intervention period absent the intervention—then the difference-in-differences regression 
estimates will be biased (16, 17). We examined the pre-SIM diagnostic prevalence and 
hospitalization rate trends between the SIM and comparison counties by modifying equation 
(1) in the following manner: changed SIM to be non-time varying, changed year to be 
continuous, and added the interaction of SIM and year. As compared with comparison 
counties, SIM counties experienced a slighter higher pre-intervention trend for diagnostic 
prevalence (1.3 percentage points higher per year, P=0.41). However, comparison counties 
experienced a decreasing pre-intervention trend that has significantly steeper than SIM 
counties’ trend for the ACSC hospitalization rate (1.9 hospitalizations per 1000 diagnosed 
adults steeper decrease per year, P<0.01) and for the all-cause hospitalization rate (5.8 
hospitalizations per 1000 diagnosed adults steeper decrease per year, P<0.01). To address 
this issue, in a second set of models we added county-year trends to equation (1) by 
interacting each county with year as a continuous variable (16, 18).
A second concern is that differences between SIM and comparison counties for the 
confounding variables in the pre-intervention period affect outcomes in the post-intervention 
period. Hence, in the second set of models we used propensity score methods to balance the 
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covariates in the pre-intervention period (19). This approach allows for statistically assessing 
whether comparison counties are equivalent to SIM counties for the confounding covariates 
after balancing. Our goal was to have the pre-intervention period’s (i.e., 2010 to 2013) 
absolute standardized differences of the variables’ means between the SIM and comparison 
counties to be less than 0.10 to 0.25 (20, 21). To operationalize this approach, we used Stata 
14.0: -probit- was used to estimate propensity scores; the propensity scores with common 
support were used to calculate stabilized inverse probability of treatment weights (IPTW) in 
the form of average treatment effect in the treated (22), which is consistent with a difference-
in-differences regression (17); and -pbalchk- was used to calculate the standardized 
difference between the SIM and comparison counties for each covariate. The IPTWs were 
used as probability weights to estimate equation (1) above (including county-year trends), 
hence, making it “doubly robust” (23). The doubly robust approach has been used to study 
the impact of Medicare hospice enrollment on costs and quality (24).
While adding county-year trends and weighting the difference-in-differences models for pre-
intervention covariate differences is designed to reduce bias, their incorporation can 
introduce bias when they are used to minimize pre-intervention outcome trends and 
covariate differences that are transient due to random noise (25–27). For example, 
minimizing the pre-SIM relative outcome trends between SIM and comparison counties 
relaxes the parallel trends assumption only if the relative trends would have continued in the 
intervention period absent the SIM intervention. In our context, it is unclear whether the 
hospitalization-rate trend differences would have persisted without SIM, for example, 
because of continuously improving diabetes care management in the comparison counties, 
or would have receded because of diminishing marginal returns, or would have even 
reversed, that is, regressed to the mean because the trend differences were actually random 
noise. Hence, we examine difference-in-differences results excluding county-year trends and 
IPTWs in the first set of models, as recommended by Lindner and McConnell (27).
This study was approved by the University of California, Berkeley, Institutional Review 
Board.
III. Results
Table 1 compares the unadjusted outcome measures, demographic characteristics and health 
characteristics for adults and for hospitalized adults diagnosed with diabetes in the SIM 
versus the comparison counties from 2010 to 2014. The diagnosed diabetes prevalence was 
higher in SIM versus the comparison counties (10.3% vs. 9.7%), while the all-cause 
hospitalization rate was lower (237.8 vs. 258.1) and ACSC hospitalization rate was similar 
(59.8 vs. 59.9). At the population level, the SIM counties were demographically similar to 
the comparison counties, with the largest difference being that 16.0% of households had 
incomes < 100% of the federal poverty level in SIM counties versus 14.7% in the 
comparison counties. Among hospitalized adults diagnosed with diabetes, the share with 
Medicaid was higher in SIM counties (22.6%) versus the comparison counties (14.3%), and 
the share admitted through the emergency department was also higher in SIM counties 
(49.9%) versus the comparison counties (32.9%). The mean number of comorbidities was 
lower in SIM counties (3.5) versus the comparison counties (3.8).
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During the study period, the unadjusted, mean diagnosed diabetes prevalence among adults 
increased in both SIM and comparison counties, and the rate of increase during the pre-SIM 
period was similar between the two sets of counties (see Figure A2 in the Appendix, 
Supplemental Digital Content 1, http://links.lww.com/MLR/B678). However, in 2014, the 
prevalence continued to increase in SIM counties while it slightly decreased in comparison 
counties. Figure 1 plots the unadjusted, mean difference in prevalence between SIM and 
comparison counties from 2010 to 2014. Before SIM implementation in 2014, the 
prevalence estimates were 0.39 to 0.76 percentage points higher in the SIM counties as 
opposed to the comparison counties. In 2014, this difference increased to 1.13 percentage 
points.
During the study period, the unadjusted, mean ACSC hospitalization rate per 1000 adults 
diagnosed with diabetes decreased in both SIM and comparison counties, but the rate 
decreased faster in comparison counties up to 2013; in 2014 the comparison rate slightly 
increased while the SIM rate slightly decreased (see Figure A3 in the Appendix, 
Supplemental Digital Content 1, http://links.lww.com/MLR/B678). Figure 2 plots the 
unadjusted, mean difference in rates between SIM and comparison counties from 2010 to 
2014. Before SIM implementation in 2014, these rates ranged from being 4.0 lower to 2.2 
higher—trending toward higher—in the SIM counties as opposed to the comparison 
counties. In 2014, this difference decreased to −0.2.
During the study period, the unadjusted, mean all-cause hospitalization rate per 1000 adults 
diagnosed with diabetes also decreased in both SIM and comparison counties, but the rate 
decreased faster in comparison counties up to 2013; in 2014 the comparison rate slightly 
increased while the SIM rate slightly decreased (see Figure A4 in the Appendix, 
Supplemental Digital Content 1, http://links.lww.com/MLR/B678). Figure 3 plots the 
unadjusted, mean difference in rates between SIM and comparison counties from 2010 to 
2014. Before SIM implementation in 2014, the hospitalization rates were 12.7 to 33.1 lower 
in the SIM counties as opposed to the comparison counties, with the trend showing a 
decrease in the difference. In 2014, the difference was 19.3.
Table 2 shows the regression parameter estimates for the difference-in-differences models 
for diagnosed diabetes prevalence among adults and the hospitalization rates per 1000 
diagnosed adults. The first column of results are based on the standard difference-in-
differences model, and the second column of results are based on the difference-in-
difference model that includes county-year trends and is estimated using IPTWs. (See Table 
A1 in the Appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/B678 that 
shows the covariate standardized differences between the SIM and comparison counties 
before and after applying IPTWs, which reduced these differences to less than 20% for each 
variable.) Compared with the pre-SIM period, the diagnosed diabetes prevalence during 
early SIM implementation increased in SIM counties by 0.65 percentage points (from 
10.22% to 10.87%), but only increased in comparison counties by 0.10 percentage points 
(from 9.64% to 9.74%), resulting in an unadjusted difference-in-differences of 0.55 
percentage points. In the table, the adjusted difference-in-differences estimate was 0.53 
percentage points (P<0.01), similar to the 0.49 percentage points (P<0.01) adjusted 
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difference-in-differences estimate that accounted for pre-SIM differences by including 
county-year trends and incorporating IPTWs.
Compared with the pre-SIM period, the hospitalization rate for ACSCs during early SIM 
implementation decreased in SIM counties by 5.6 (from 60.9 to 55.3), similar to the 
decrease in comparison counties of 5.5 (from 61.0 to 55.5), resulting in an unadjusted 
difference-in-differences of −0.1. In the table, the adjusted difference-in-differences estimate 
was −0.4 (P=0.75). In contrast, the adjusted difference-in-differences estimate that 
accounted for pre-SIM differences was −5.3 (P<0.01) because the hospitalization rate for 
ACSCs was decreasing more quickly in comparison counties relative to SIM counties prior 
to the SIM intervention.
Compared with the pre-SIM period, the all-cause hospitalization rate during early SIM 
implementation decreased in SIM counties by 15.2 (from 240.8 to 225.6), similar to the 
decrease in comparison counties of 16.4 (from 261.4 to 245.0) resulting in an unadjusted 
difference-in-differences of 1.2. In the table, the adjusted difference-in-differences estimate 
was 0.92 (P=0.81). In contrast, the adjusted difference-in-differences estimate that accounted 
for pre-SIM differences was −13.2 (P<0.01) because the all-cause hospitalization rate was 
decreasing more quickly in comparison counties relative to SIM counties prior to the SIM 
intervention.
IV. Discussion
The results indicate that the first year of the CMS SIM Initiative Round 1 test award was 
associated with higher diagnosed diabetes prevalence among adults, but results related to 
lower ACSC and all-cause hospitalization rates among adults diagnosed with diabetes are 
mixed and sensitive to model specification decisions. Compared with comparison counties, 
SIM counties on average experienced between a 0.49 to 0.53 percentage point higher 
regression-adjusted increase in diagnostic prevalence before versus after SIM 
implementation. Based on the adult population in SIM counties totaling 15.9 million in 
2014, the two estimated increases in diagnostic prevalence would have led to between 
77,910 (95% confidence interval: 52,470—103,350) and 84,270 (95% confidence interval: 
62,010—106,530) newly diagnosed adults. The implementation of SIM may have 
contributed to improving detection of diabetes through increased screening, particularly in 
high-risk populations with limited access to health care. Earlier detection of diabetes via 
screening has been linked to lower health care costs (28). Furthermore, improved detection 
of diabetes is associated with better outcomes, because undiagnosed diabetes has been found 
to be associated with more hospitalizations, longer lengths of stay, and increased mortality 
(29).
However, the first year of SIM implementation in Round 1 was not found to be consistently 
associated with a lower hospitalization rate, either for ACSCs or all-causes, which may have 
been due to the initiative’s design and incentives as well as the capabilities of the health care 
providers. Reviews of studies on accountable care organizations (30) and patient-centered 
medical homes (31, 32), both which share delivery-system and payment-reform attributes of 
SIM, found evidence that these programs can have a positive impact on health care 
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utilization, quality, and health outcomes, but the results were mixed and depended on a 
program’s design, financial incentives, and patient population. For example, delivery and 
payment reforms have modestly reduced health care spending, including hospital 
expenditures, in the short term among early provider participants, likely because they had 
more advanced systems to manage care (33). Better management of hemoglobin A1c levels 
may reduce hospitalizations, because higher hemoglobin A1c levels are a predictor of 
hospitalizations in adults with diagnosed diabetes, undiagnosed diabetes, and pre-diabetes 
(34). Future research will evaluate the long-term effects of the SIM Initiative (35).
When pre-intervention hospitalization rate trend differences were accounted for in 
regression models, then SIM was estimated to reduce both the ACSC and all-cause 
hospitalization rates among adults diagnosed with diabetes. In the pre-intervention period, 
these hospitalization rates were decreasing faster in the comparison counties, but the relative 
trends reversed in the post-intervention period. Because we do not know whether the pre-
intervention trends would have continued in the post-intervention period (absent SIM), the 
interpretation of this finding is unclear. On the one hand, the non-parallel trends may have 
continued if existing healthcare delivery, payment reform and unobserved demographic 
factors continued to improve in the comparison counties relative to the SIM counties. On the 
other hand, the non-parallel trends may not have continued if there were diminishing effects 
of these factors over time.
This study has limitations that warrant discussion. First, a difference-in-differences 
regression model assumes there was not an intervention that occurred contemporaneously 
with SIM that affected diagnosed diabetes prevalence among adults or hospitalization rates 
among diagnosed adults. During 2014, the majority of the Affordable Care Act’s insurance 
expansion occurred, but there was significant county-level heterogeneity. However, our 
models controlled for each county’s uninsured rate. Eleven of the 12 states in our models 
expanded Medicaid in 2014, with the exception being Maine (36). Therefore, we do not 
think the Affordable Care Act’s insurance expansion biased the parameter estimates. 
However, during 2014, the Center for Medicare and Medicaid Innovation sponsored several 
initiatives similar to SIM, including primary care initiatives, accountable care organization 
models, and efforts to improve the care of Medicare-Medicaid dually eligible patients (37). 
These initiatives may have affected diagnostic prevalence and hospitalization rates for 
diagnosed adults differently between SIM and comparison counties, but it was not feasible 
to measure and incorporate these initiatives into our analyses. In addition, the SIM Initiative 
is implemented differently across states and not uniformly among counties within states. 
Hence, this would attenuate the measured effects of SIM, because in some counties, it may 
not have been implemented to target diabetes detection and management. Finally, lack of 
statistical power limited our ability to estimate heterogeneous effects by stratifying SIM 
states based on implementation foci, but that will be possible in a future study that includes 
all 12 SIM Round 1 and Round 2 states as treatment states with a longer post-intervention 
period (2014 to 2017) (35).
Preventing, diagnosing and managing diabetes is a high priority for most states, because of 
its increasing prevalence and growing economic burden (5, 7). The CMS SIM Initiative 
appears to have had early promise in accelerating improvements in diabetes detection, but 
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has yet to clearly show improved management at the population-level with respect to 
hospitalization rates among diagnosed adults. When the SIM Initiative Round 1 and 2 states 
have completed their SIM implementation and that data become available, it will be 
important to assess whether the foci and resourcing of SIM among states were differentially 
associated with improved diabetes detection. Given the latitude CMS gave states when 
developing their SIM plans, identifying the specific reforms and investments used by states 
with relatively more success in improving outcomes could improve the nation’s overall 
investment in state-led innovation.
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Figure 1: Unadjusted, Mean Differences in Diagnosed Diabetes Prevalence Among Adults for 
SIM versus Comparison Counties, 2010–2014
Notes: SIM funding began on Apr 1, 2013, which included an initial 6-month test period, 
resulting in the test implementation phase beginning Oct 1, 2013. Because the diagnosed 
diabetes prevalence data is annual, we modeled the implementation period as beginning Jan 
1, 2014. Prevalence differences were calculated each year by subtracting the mean of the 
county-level prevalence in the 240 SIM counties from the mean of the county-level 
prevalence in the 343 comparison counties. The error bars are 95% confidence intervals of 
the difference in the mean prevalence by year. Apr indicates April; Dec, December; Jan, 
January; Oct, October; SIM, State Innovation Model
Source: Authors’ analysis of Centers for Disease Control and Prevention’s county-level 
estimates
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Figure 2: Unadjusted, Mean Differences in ACSC Hospitalization Rate per 1000 Adults 
Diagnosed with Diabetes for SIM versus Comparison Counties, 2010–2014
Notes: SIM funding began on Apr 1, 2013, which included an initial 6-month test period, 
resulting in the test implementation phase beginning Oct 1, 2013. Because the diagnosed 
diabetes prevalence data is annual, we modeled the implementation period as beginning Jan 
1, 2014. Hospital rate differences were calculated each year by subtracting the mean of the 
county-level hospitalization rate in the 240 SIM counties from the mean of the county-level 
hospitalization rate in the 343 comparison counties. The error bars are 95% confidence 
intervals of the difference in the mean hospitalization rate by year. ACSC indicates 
ambulatory care-sensitive condition; Apr, April; Dec, December; Jan, January; Oct, October; 
SIM, State Innovation Model
Sources: Authors’ analysis of Centers for Disease Control and Prevention’s county-level 
estimates and Healthcare Cost and Utilization Project’s State Inpatient Databases
Fulton et al. Page 14
Med Care. Author manuscript; available in PMC 2020 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3: Unadjusted, Mean Differences in All-Cause Hospitalization Rate per 1000 Adults 
Diagnosed with Diabetes for SIM versus Comparison Counties, 2010–2014
Notes: SIM funding began on Apr 1, 2013, which included an initial 6-month test period, 
resulting in the test implementation phase beginning Oct 1, 2013. Because the diagnosed 
diabetes prevalence data is annual, we modeled the implementation period as beginning Jan 
1, 2014. Hospital rate differences were calculated each year by subtracting the mean of the 
county-level hospitalization rate in the 240 SIM counties from the mean of the county-level 
hospitalization rate in the 343 comparison counties. The error bars are 95% confidence 
intervals of the difference in the mean hospitalization rate by year. Apr indicates April; Dec, 
December; Jan, January; Oct, October; SIM, State Innovation Model
Sources: Authors’ analysis of Centers for Disease Control and Prevention’s county-level 
estimates and Healthcare Cost and Utilization Project’s State Inpatient Databases
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Table 1:
County-Level Outcomes, Demographics, and Health Characteristics of the Adult Population and Hospitalized 
Adults Diagnosed with Diabetes for SIM versus Comparison Counties, 2010 to 2014
Variable SIM Counties
(mean)
SIM Counties
(std dev)
Comparison 
Counties
(mean)
Comparison 
Counties
(std dev)
Difference P-value
Outcome Variables (levels)
Diagnosed diabetes prevalence 
(%)
10.3 2.3 9.7 2.0 0.7 <0.001
All-cause hospitalizations per 
1000 adults diagnosed with 
diabetes
237.8 76.1 258.1 76.1 −20.3 0.002
ACSC hospitalizations per 1000 
adults diagnosed with diabetes
59.8 20.9 59.9 20.7 −0.2 0.924
Outcome Variables (annual change)
Diagnosed diabetes prevalence 
(pp)
0.20 0.30 0.10 0.30 0.10 <0.001
All-cause hospitalizations per 
1000 adults diagnosed with 
diabetes
−7.5 18.8 −10.9 22.1 3.3 0.058
ACSC hospitalizations per 1000 
adults diagnosed with diabetes
−2.5 5.0 −3.5 6.5 1.0 0.039
Adult Population Independent Variables (%)
Female* 50.3 1.4 49.8 2.1 0.6 <0.001
Age 20−39 y 32.1 5.3 31.8 6.3 0.2 0.622
Age 40−64 y 44.9 2.7 45.4 3.3 −0.6 0.022
Age 65+ y 23.1 4.6 22.7 4.9 0.3 0.395
Nonwhite* 15.5 13.4 15.1 13.6 0.4 0.725
Uninsured* 14.0 5.4 13.4 4.0 0.6 0.098
Household income less than 
100% FPL*
16.0 5.8 14.7 4.6 1.3 0.003
Hospitalized Adults Diagnosed with Diabetes (% unless indicated)
Female 51.0 4.0 49.9 3.4 1.1 <0.001
Age 20−44 y 7.9 2.7 7.0 2.5 0.8 <0.001
Age 45–64 y 31.3 5.4 31.5 5.5 −0.1 0.767
Age 65+ y 60.8 7.4 61.5 7.3 −0.7 0.264
Nonwhite 14.4 15.6 11.1 14.6 3.4 0.020
Medicaid 22.6 10.3 14.3 9.0 8.3 <0.001
Admitted from emergency 
department
49.9 20.4 32.9 27.9 17.0 <0.001
Number of comorbidities 
(mean)
3.5 0.4 3.8 0.3 −0.3 <0.001
*
Due to data availability, these statistics are based on the total population in a county, not just the adult population.
ACSC indicates ambulatory care-sensitive conditions; FPL: federal poverty level; pp: percentage points; SIM: State Innovation Model; Std dev: 
standard deviation
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Notes: Statistics are based on county-level data, including 240 SIM counties and 343 comparison counties, for years 2010–2014 combined. The 
reported differences may not equal the differences between SIM and comparison counties due to rounding.
Sources: Authors’ analysis Centers for Disease Control and Prevention’s county-level estimates, Healthcare Cost and Utilization Project’s State 
Inpatient Databases, and Area Health Resources File
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Table 2:
Difference-in-Differences Regression Results for Diagnosed Diabetes Prevalence and Hospitalization Rates
Difference-in-Differences
(N=2,915)
Difference-in-Differences
(accounts for pre-SIM differences)
(N=2,900)
Coefficient Estimate 95% Confidence Interval Coefficient Estimate 95% Confidence Interval
Variable Diagnosed Diabetes Prevalence
SIM Initiative 0.53*** (0.39, 0.67) 0.49*** (0.33, 0.65)
Female −0.03 (−0.22, 0.15) 0.07 (−0.13, 0.28)
Age 40–64 y 0.02 (−0.07, 0.10) 0.08 (−0.04, 0.20)
Age 65+ y 0.03 (−0.06, 0.12) −0.05 (−0.20, 0.10)
Nonwhite 0.03 (−0.10, 0.15) 0.10 (−0.06, 0.26)
Uninsured
−0.05*** (−0.08, −0.02) −0.02 (−0.05, 0.01)
Household income < 100% FPL 0.00 (−0.02, 0.03) −0.01 (−0.03, 0.01)
Year 2011 0.26*** (0.19, 0.33) 0.32*** (0.18, 0.46)
Year 2012 0.33*** (0.20, 0.46) 0.54*** (0.27, 0.80)
Year 2013 0.42*** (0.23, 0.61) 0.73*** (0.33, 1.12)
Year 2014 0.11 (−0.18, 0.39) 0.62** (0.06, 1.19)
Constant 10.11* (−0.55, 20.77) 2.55 (−11.18, 16.27)
Variable Ambulatory Care-Sensitive Condition Hospitalization Rate
SIM Initiative −0.37 (−2.64, 1.89)
−5.34*** (−8.54, −2.14)
Female 0.24 (−6.73, 7.21) −1.86 (−8.30, 4.58)
Age 40–64 y 1.87* (−0.15, 3.89) 0.36 (−2.75, 3.48)
Age 65+ y 2.39** (0.07, 4.70) 1.60 (−2.67, 5.87)
Nonwhite −1.35 (−4.01, 1.31) −1.63 (−5.84, 2.58)
Uninsured 0.34 (−0.22, 0.90) −0.43 (−1.19, 0.34)
Household income < 100% FPL 0.03 (−0.41, 0.46) 0.21 (−0.20, 0.63)
Year 2011
−3.07*** (−4.68, −1.47) −6.78*** (−10.35, −3.21)
Year 2012
−9.39*** (−11.97, −6.81) −17.16*** (−24.24, −10.08)
Year 2013
−10.72*** (−14.58, −6.85) −21.78*** (−32.55, −11.02)
Year 2014
−9.44*** (−15.01, −3.86) −24.96*** (−40.26, −9.66)
Constant −69.06 (−445.14, 307.01) 137.44 (−230.64, 505.51)
Variable All-Cause Hospitalization Rate
SIM Initiative 0.92 (−6.67, 8.51)
−13.16*** (−21.34, −4.97)
Female −3.57 (−23.69, 16.54) −7.01 (−20.65, 6.62)
Age 40–64 y 5.37 (−1.50, 12.25) 0.19 (−8.54, 8.92)
Age 65+ y 5.30 (−1.41, 12.01) 7.57 (−3.43, 18.57)
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Difference-in-Differences
(N=2,915)
Difference-in-Differences
(accounts for pre-SIM differences)
(N=2,900)
Coefficient Estimate 95% Confidence Interval Coefficient Estimate 95% Confidence Interval
Nonwhite
−7.01* (−14.92, 0.89) −10.05** (−18.87, −1.24)
Uninsured 1.68* (−0.09, 3.45) −0.37 (−2.12, 1.38)
Household income < 100% FPL 0.18 (−1.14, 1.50) 0.14 (−1.02, 1.30)
Year 2011
−12.52*** (−16.77, −8.27) −20.35*** (−28.77, −11.94)
Year 2012
−27.63*** (−35.40, −19.86) −48.06*** (−64.93, −31.19)
Year 2013
−29.32*** (−42.45, −16.20) −59.05*** (−83.81, −34.30)
Year 2014
−21.33** (−38.82, −3.83) −63.59*** (−98.84, −28.34)
Constant 163.64 (−956.63, 1283.91) 607.29 (−228.75, 1443.34)
*P<0.10,
**P<0.05,
***P<0.01
FPL indicates federal poverty level; SIM, State Innovation Model
County fixed effects and county-year trend parameter estimates not shown. For the county-year trends, year was coded as a continuous variable 
equal to the actual year minus 2010 so the first value would be zero; this coding only affects the estimate of the constant. Hospitalization rate is the 
number of hospitalizations per 1000 adults diagnosed with diabetes. The reference group for age was 20–39 year olds and for year was 2010. The 
sample size for the difference-in-differences model that accounted for pre-SIM differences had a smaller sample size due to dropping counties 
without common support.
Sources: Authors’ analysis of Centers for Disease Control and Prevention’s county-level estimates, Healthcare Cost and Utilization Project’s State 
Inpatient Databases, and Area Health Resources File
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